Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


oral

Oral

APR has a long experience in the oral pharmaceutical and nutraceutical formulations: a dynamic approach coupled with a solid background enables APR to offer the best and the most complete R&D support starting from galenic phase to a complete Dossier ready for filing.

APR has many years experience on the following pharmaceutical dosage forms:
> Conventional tablets
> Bi-layer tablets
> Micro-tablets
> Capsules
> Granulates
> Oral Dispersible Film (ODF)
> Oral Dispersible Tablets (ODT)
> Oral Dispersible Powder (ODP)

About Release Profile, APR is able to work and design the following profiles:
> Conventional release
> Immediate release
> Fast release
> Delayed release
> Dual Release (Fast and Extended)
> Prolonged/Extended release
> Taste masked formulation

About manufacturing processes, APR's experience ranges through all the following techniques:
> Direct Compression;
> Dry and Wet Granulation;
> Melt granulation;
> Cosmetic and Functional coating.




Search results